Wandeldarlehen vs SAFE:
How German Startups Really Raise Pre-Seed

Short answer

A German startup raising pre-seed should usually use a Wandeldarlehen (convertible loan), not a US-style SAFE. German GmbH law has no authorized-share mechanism, so a SAFE's automatic conversion cannot be executed; new shares only exist after a notarized capital increase. A Wandeldarlehen delivers similar speed with terms German investors and courts recognize.

SAFEs closed 93% of US pre-seed deals on Carta in Q4 2025 — near-total dominance. Pitch the same document to a Munich business angel and you'll usually get a polite counter-offer: a Wandeldarlehen. This guide breaks down the Wandeldarlehen vs SAFE decision — how each instrument works, why German corporate law quietly breaks the SAFE, and a decision rule based on where your Series A money will actually come from.

Should a German startup use a SAFE or a Wandeldarlehen?

For a German GmbH or UG raising from German or EU investors, the Wandeldarlehen is the default — and for good reason, not just habit. A SAFE is a creature of Delaware corporate law. It works because a US corporation holds authorized but unissued shares that convert automatically when a priced round closes. A GmbH has nothing comparable: shares come into existence only through a capital increase, resolved by shareholders in front of a notary and registered in the commercial register. As BERLIN tax & legal puts it, automatic conversion in the Y Combinator sense is simply not executable under German law.

That single mechanical difference explains most of the gap between the two markets. In the US, Carta's State of Pre-Seed data shows SAFEs at a record 93% of pre-seed rounds in Q4 2025, with convertible notes down to 7%. In Germany, the convertible loan — a real loan with interest, a maturity date and a conversion right — remains the standard pre-seed instrument, because it gives investors downside protection German law can actually enforce.

How a Wandeldarlehen works

A Wandeldarlehen is a loan agreement combined with the right (or obligation) to convert the outstanding amount into shares at your next financing round. The investor wires money now; instead of pricing your company today, everyone lets the next priced round set the valuation.

The moving parts you'll negotiate:

1. Principal and interest. Interest accrues rather than being paid in cash, and usually converts into shares together with the principal.
2. Conversion discount. Typically 15–25% off the next round's share price, per Orrick's convertible loan guide — compensation for taking risk earlier.
3. Valuation cap. A ceiling on the conversion price. In a hot round, the cap — not the discount — decides the investor's stake, so model both before signing.
4. Maturity. German convertible loans carry a fixed term, commonly one to three years. If no round happens, the loan falls due — repayment, extension, or conversion at a pre-agreed fallback valuation.
5. Qualified subordination (qualifizierter Rangrücktritt). Because the loan is balance-sheet debt, a subordination clause keeps it from pushing an early-stage company into technical over-indebtedness. Never skip this.
6. Conversion right vs obligation. Who must convert, and when? An investor obligation to convert protects you from a surprise repayment demand — but it also feeds the notarization debate below.

One founder-side warning: a Wandeldarlehen is still debt until it converts. Stack three or four of them with different caps and maturities and you've built a repayment cliff and a messy conversion waterfall for your seed round. Keep terms uniform across your pre-seed lenders wherever possible.

Why the US SAFE doesn't port cleanly to Germany

Founders who've read US blogs often push for a SAFE because it has no interest, no maturity and no repayment — strictly friendlier terms on paper. Three problems appear when you drop it into a German structure:

• No automatic conversion. Every issuance of new GmbH shares requires a notarized shareholders' resolution and registration. The SAFE's core promise — friction-free conversion — can only be replicated by contractual obligations to cooperate in a future notarized capital increase. That's exactly what a Wandeldarlehen already does.
• Unclear legal and tax classification. German practice treats the SAFE either as a special form of convertible loan or as an atypical instrument with profit-participation characteristics, per the ITMediaLaw comparison. Ambiguity about whether the money is debt or equity creates accounting and tax questions no pre-seed round needs.
• Form requirements are disputed even for convertible loans. Since the OLG Zweibrücken ruling in case 8 U 30/19 — which reached the Federal Court of Justice — German lawyers have debated when a convertible instrument must be notarized, especially where the investor is obliged to convert. Cautious counsel notarizes in cases of doubt. An un-notarized US-template SAFE sits at the risky end of that debate: worst case, the conversion promise is void and your investor is holding an unsecured claim.

There's also a cultural layer. German angels grew up on instruments where, if the startup stalls, they're creditors with a repayment claim — not holders of a contract that may be worth nothing. Asking them to give that up costs you negotiating capital better spent on the cap and discount.

Wandeldarlehen vs SAFE at a glance

Decide by your next investor's passport

Here's the decision rule most comparisons miss: the instrument question is really a question about who leads your next priced round, not about which document is friendlier.

• Your seed and Series A will be German or European. Use a Wandeldarlehen. Your future lead's lawyers will expect one, diligence will be faster, and you avoid re-papering US-style documents into German law mid-round.
• You're targeting US funds and accelerators. Many will require a Delaware entity anyway. In that case the clean sequence is: complete the Delaware flip, then raise on standard post-money SAFEs at the TopCo level — not before.
• Genuinely unsure. Take the Wandeldarlehen, but negotiate US-friendly conversion language: clear treatment in a future share exchange or flip, and no clauses that would surprise a Delaware lawyer during diligence.

The mistake that costs real money is the hybrid: signing a US SAFE template against a German GmbH to look "international". You get the SAFE's weaker investor protections and German-law execution risk — the worst quadrant of the matrix.

What this means for you

Instrument choice is downstream of your fundraising strategy. Before you send anyone a draft, decide three things: which market your seed lead will come from, how much debt your balance sheet can carry with subordination, and what cap you can defend with seed round benchmarks rather than hope. Then have German counsel paper it — a standard Wandeldarlehen costs far less in legal fees than untangling a defective SAFE in Series A diligence. And remember the cap and discount you sign now behave exactly like the term sheet clauses that actually cost you later: small percentages, compounding consequences. If you want to grow without touching equity at all, grants and other non-dilutive funding routes are worth exhausting first.